Andrew Dunn Healthcare Reporter
  • Washington, D.c.
  • Business Insider

Andrew Dunn is a healthcare reporter at Business Insider, covering the pharmaceutical and biotechnology industries.

Focus Areas

  • Healthcare
  • Pharmaceutical Industry
  • Biotechnology Industry

241 Articles
8 days ago
businessinsider.com

The most expensive drug in the world just got approved at $3.5 million, and hemophilia patients a...

Patients with the blood disorder hemophilia told Insider they're excited about the new gene therapy but worried over ...

Read Full Article
9 days ago
businessinsider.com

How the founder of SiriusXM wants to tackle an organ shortage with 3D-printed hearts and lungs

After founding SiriusXM in the 1990s, Martine Rothblatt is now running a biotech pushing the boundary of what's possi...

Read Full Article
18 days ago
businessinsider.com

A former Harvard chemist just raised $178 million for a biotech startup that plans to treat previ...

FogPharma is now on the cusp of starting human testing for a game-changing cancer drug, CEO Greg Verdine told Insider.

Read Full Article
23 days ago
businessinsider.com

See the 25-slide pitch deck a Baltimore biotech used to raise $56 million to develop a blood test...

Haystack hopes to detect tiny, lingering traces of cancer in a person's body to help stop tumors from coming back.

Read Full Article
about 1 month ago
businessinsider.com

We're closer to getting the first new pill to treat UTIs in over 20 years

The antibiotic succeeded in late-stage human studies, setting up the drug to be a new treatment for urinary tract inf...

Read Full Article
about 2 months ago
businessinsider.com

CRISPR pioneer Feng Zhang is building a secretive new startup to solve gene-editing's biggest pro...

Backed by GV and Arch Venture Partners, the stealth startup Aera Therapeutics is trying to solve gene-editing's big d...

Read Full Article
about 2 months ago
businessinsider.com

Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn

Biotech startups specializing in gene editing aren't just surviving but thriving through a rocky stock market, driven...

Read Full Article
2 months ago
businessinsider.com

See the 12-slide pitch deck a Flagship startup just used to raise $121 million to build an 'unlim...

Flagship, the venture-creation firm behind Moderna, led a $121 million Series C round for Cellarity, a biotech mappin...

Read Full Article
2 months ago
businessinsider.com

Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech's 282-page filing...

Prime is hoping to dodge an icy IPO market in biotech, reportedly planning to raise up to $200 million.

Read Full Article
2 months ago
businessinsider.com

A biotech trying to bring back the woolly mammoth just launched its first spinout company. See th...

While Colossal chases the ambitious idea of resurrecting the woolly mammoth, its CEO says spinoffs like Form Bio are ...

Read Full Article
3 months ago
businessinsider.com

Embattled CEO Werner Baumann enters his final chapter at Bayer, aiming to turn the German pharma ...

After championing the controversial Monsanto acquisition, Bayer CEO Werner Baumann's contract is set to expire in 2024.

Read Full Article
3 months ago
businessinsider.com

We went inside the lab at Vertex, a company that dodged the market downturn to become one of the ...

The Boston biotech has risen to the top ranks of the drug industry, and it's betting big that a unique research strat...

Read Full Article

Copyright © 2021 All rights reserved. Legitimate Limited.